Cancer News and Research

Latest Cancer News and Research

AdnaGen signs option agreement to license specific antibodies to KellBenx

AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc., a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments, today announced that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a New York-based private biotech firm.

19 Jun 2010

Conscious sedation for glioma resection shortens hospital stay

The recovery time and cost of brain-tumor surgery might both be reduced if surgery is performed while patients are awake during part of the procedure, according to a new study conducted at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

19 Jun 2010

Investigators discover new way to harness thrombin's anti-blood clotting properties

In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S.

19 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

Akela Pharma first-quarter net loss reduces to $0.4 million

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months ended March 31, 2010.

19 Jun 2010

LUHS opens clinic to treat debilitating effects of CPP in women

Loyola University Health System has opened a clinic to treat the debilitating effects of chronic pelvic pain in women. The clinic is located at the Loyola Outpatient Center at 2160 S. First Ave., in Maywood.

19 Jun 2010

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

The Republic of Equatorial Guinea (Republica de Guinea Ecuatorial, along with the United Nations Population Fund (UNFPA), is working to strengthen and equip health facilities throughout the country to boost access to reproductive health services. The rebuilding process includes the construction and renovation of health centers and maternity units as well as proper training for medical students.

19 Jun 2010

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City. The focus represents a growing interest and validation of how PEM can play an important role in the fight against breast cancer.

18 Jun 2010

National Cheng Kung University Hospital's Outpatient Building inaugurated

The Outpatient Building of National Cheng Kung University Hospital was officially inaugurated on June 12th to provide excellent medical service and to further ensure the health of people in Southern Taiwan.

18 Jun 2010

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.

18 Jun 2010

Genzyme signs repurchase agreement with Goldman, Sachs

Genzyme Corporation announced today that it has entered into an agreement with Goldman, Sachs & Co. to repurchase $1 billion of Genzyme common stock under an accelerated stock repurchase program. Proceeds from its recently concluded debt offering will be used to support this first tranche of Genzyme's overall $2 billion share repurchase plan announced in May.

18 Jun 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.

18 Jun 2010

FVL gene mutation increases risk of blood clots in breast cancer patients treated with tamoxifen: Study

Women who develop blood clots while taking tamoxifen for early-stage breast cancer are more likely to carry a faulty version of a gene involved in clotting than those who do not develop blood clots, a US study has found.

18 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

The expression of a transporter protein called the Breast Cancer Resistance Protein in rheumatoid arthritis patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs, according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

NeoStem announces presentation on very small embryonic-like stem cells at ISSCR 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that a poster authored by NeoStem-affiliated scientists will be presented in a presentation at the premier stem cell research event, the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting in San Francisco on June 17, 2010.

18 Jun 2010

Hyperthermia in combination with particle therapy highlighted at DEGRO annual meeting

BSD Medical Corporation today announced that hyperthermia in conjunction with particle therapy was highlighted at the annual meeting of the German Society of Radiation Oncology, which was recently held in Magdeburg, Germany. A total of 2,500 scientists and radiation oncologists attended the meeting.

18 Jun 2010

Encouraging interim results from stem and regenerative cell-enriched fat grafting breast reconstruction trial

Interim results from a breast reconstruction trial show stem and regenerative cell-enriched fat grafting resulted in a high sustained rate of physician and patient satisfaction and persistent improvements in overall outcomes of the procedure at six and 12 months.

18 Jun 2010

Cancer News and Research

Latest Cancer News and Research

AdnaGen signs option agreement to license specific antibodies to KellBenx

Conscious sedation for glioma resection shortens hospital stay

Investigators discover new way to harness thrombin's anti-blood clotting properties

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

SAHM strongly recommends HPV vaccines for males

Akela Pharma first-quarter net loss reduces to $0.4 million

LUHS opens clinic to treat debilitating effects of CPP in women

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

National Cheng Kung University Hospital's Outpatient Building inaugurated

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Genzyme signs repurchase agreement with Goldman, Sachs

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

FVL gene mutation increases risk of blood clots in breast cancer patients treated with tamoxifen: Study

BioSante announces presentation of LibiGel safety update at ENDO 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

NeoStem announces presentation on very small embryonic-like stem cells at ISSCR 2010

Hyperthermia in combination with particle therapy highlighted at DEGRO annual meeting

Encouraging interim results from stem and regenerative cell-enriched fat grafting breast reconstruction trial

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in